These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Economic evaluation of high-dose inactivated influenza vaccine in adults aged ≥65 years: A systematic literature review. Colrat F; Thommes E; Largeron N; Alvarez FP Vaccine; 2021 Mar; 39 Suppl 1():A42-A50. PubMed ID: 33518466 [TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness and public health impact of alternative influenza vaccination strategies in high-risk adults. Raviotta JM; Smith KJ; DePasse J; Brown ST; Shim E; Nowalk MP; Wateska A; France GS; Zimmerman RK Vaccine; 2017 Oct; 35(42):5708-5713. PubMed ID: 28890196 [TBL] [Abstract][Full Text] [Related]
24. Cost-Effectiveness and Public Health Effect of Influenza Vaccine Strategies for U.S. Elderly Adults. Raviotta JM; Smith KJ; DePasse J; Brown ST; Shim E; Nowalk MP; Zimmerman RK J Am Geriatr Soc; 2016 Oct; 64(10):2126-2131. PubMed ID: 27709600 [TBL] [Abstract][Full Text] [Related]
25. A retrospective cohort study assessing relative effectiveness of adjuvanted versus high-dose trivalent influenza vaccines among older adults in the United States during the 2018-19 influenza season. Pelton SI; Divino V; Postma MJ; Shah D; Mould-Quevedo J; DeKoven M; Krishnarajah G Vaccine; 2021 Apr; 39(17):2396-2407. PubMed ID: 33810903 [TBL] [Abstract][Full Text] [Related]
26. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. DiazGranados CA; Dunning AJ; Kimmel M; Kirby D; Treanor J; Collins A; Pollak R; Christoff J; Earl J; Landolfi V; Martin E; Gurunathan S; Nathan R; Greenberg DP; Tornieporth NG; Decker MD; Talbot HK N Engl J Med; 2014 Aug; 371(7):635-45. PubMed ID: 25119609 [TBL] [Abstract][Full Text] [Related]
28. Safety and immunogenicity of high-dose trivalent inactivated influenza vaccine in adults 50-64 years of age. DiazGranados CA; Saway W; Gouaux J; Baron M; Baker J; Denis M; Jordanov E; Landolfi V; Yau E Vaccine; 2015 Dec; 33(51):7188-7193. PubMed ID: 26555348 [TBL] [Abstract][Full Text] [Related]
29. Evaluating the Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine Compared to High-Dose Trivalent and Other Egg-Based Influenza Vaccines among Older Adults in the US during the 2017-2018 Influenza Season. Pelton SI; Divino V; Shah D; Mould-Quevedo J; DeKoven M; Krishnarajah G; Postma MJ Vaccines (Basel); 2020 Aug; 8(3):. PubMed ID: 32784684 [TBL] [Abstract][Full Text] [Related]
31. Assessment of potential public health impact of a quadrivalent inactivated influenza vaccine in Thailand. Kittikraisak W; Chittaganpitch M; Gregory CJ; Laosiritaworn Y; Thantithaveewat T; Dawood FS; Lindblade KA Influenza Other Respir Viruses; 2016 May; 10(3):211-9. PubMed ID: 26588892 [TBL] [Abstract][Full Text] [Related]
32. Monitoring the safety of high-dose, trivalent inactivated influenza vaccine in the vaccine adverse event reporting system (VAERS), 2011 - 2019. Moro PL; Woo EJ; Marquez P; Cano M Vaccine; 2020 Aug; 38(37):5923-5926. PubMed ID: 32709434 [TBL] [Abstract][Full Text] [Related]
34. Effectiveness of Trivalent and Quadrivalent Inactivated Vaccines Against Influenza B in the United States, 2011-2012 to 2016-2017. Gaglani M; Vasudevan A; Raiyani C; Murthy K; Chen W; Reis M; Belongia EA; McLean HQ; Jackson ML; Jackson LA; Zimmerman RK; Nowalk MP; Monto AS; Martin ET; Chung JR; Spencer S; Fry AM; Flannery B Clin Infect Dis; 2021 Apr; 72(7):1147-1157. PubMed ID: 32006430 [TBL] [Abstract][Full Text] [Related]
35. Cumulative clinical experience with MF59-adjuvanted trivalent seasonal influenza vaccine in young children. Patel SS; Bizjajeva S; Lindert K; Heijnen E; Oberye J Int J Infect Dis; 2019 Aug; 85S():S26-S38. PubMed ID: 31096055 [TBL] [Abstract][Full Text] [Related]
36. Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: A phase 3 randomized clinical trial. Chang LJ; Meng Y; Janosczyk H; Landolfi V; Talbot HK; Vaccine; 2019 Sep; 37(39):5825-5834. PubMed ID: 31431411 [TBL] [Abstract][Full Text] [Related]
37. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2019-20 Influenza Season. Grohskopf LA; Alyanak E; Broder KR; Walter EB; Fry AM; Jernigan DB MMWR Recomm Rep; 2019 Aug; 68(3):1-21. PubMed ID: 31441906 [TBL] [Abstract][Full Text] [Related]
38. A Novel Dynamic Model for Health Economic Analysis of Influenza Vaccination in the Elderly. Mullikin M; Tan L; Jansen JP; Van Ranst M; Farkas N; Petri E Infect Dis Ther; 2015 Dec; 4(4):459-87. PubMed ID: 26350238 [TBL] [Abstract][Full Text] [Related]
39. An Assessment of the Expected Cost-Effectiveness of Quadrivalent Influenza Vaccines in Ontario, Canada Using a Static Model. Chit A; Roiz J; Aballea S PLoS One; 2015; 10(7):e0133606. PubMed ID: 26222538 [TBL] [Abstract][Full Text] [Related]
40. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial. Vesikari T; Kirstein J; Devota Go G; Leav B; Ruzycky ME; Isakov L; de Bruijn M; Oberye J; Heijnen E Lancet Respir Med; 2018 May; 6(5):345-356. PubMed ID: 29631857 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]